Tessera Defense and Homeland Security Inc. (HLSQ) is a NYSE American-listed physical security technology company that operates a unified platform connecting cameras, sensors, detection technologies, artificial intelligence and other security infrastructure. News related to Tessera often focuses on how the company develops and deploys integrated security solutions for homeland security, critical infrastructure, energy, digital infrastructure and enterprise environments.
Coverage of Tessera can include announcements about enhancements to its unified security platform, updates on deployments that connect detection, intelligence and response across complex sites, and developments involving its subsidiaries. Zorronet, which provides AI-powered security intelligence and autonomous command-and-control capabilities, and DFSL, which develops LADAR-based counter-UAS and perimeter security systems, may feature in reports about advanced sensing, real-time intelligence and autonomous response applications.
Another important theme in Tessera-related news is its corporate evolution. On September 11, 2026, the company changed its legal name from BiomX Inc. to Tessera Defense and Homeland Security Inc. and began trading under the HLSQ ticker, replacing PHGE. Articles and releases may reference this transition and explain that older items under the BiomX name or PHGE symbol document the issuer’s former biotechnology business rather than its current security focus.
Investors, analysts and security professionals following Tessera’s news can expect information about platform capabilities, customer segments such as critical infrastructure and homeland security organizations, and the company’s role in addressing evolving physical threats, including those involving unmanned and autonomous systems. Historical news under the BiomX identity remains part of the record but should be interpreted in light of the company’s subsequent shift to physical security technology.
BiomX Inc. (NYSE American: PHGE) is set to hold a conference call on November 15, 2021, at 8:00 a.m. EDT to discuss third quarter 2021 financial results and provide business updates. The live audio webcast can be accessed through the company's website.
BiomX is a clinical-stage microbiome company focusing on novel phage therapies targeting pathogenic bacteria, impacting various chronic diseases including inflammatory bowel disease and colorectal cancer.
BiomX announced results from its Phase 2 clinical study of BX001, a topical treatment for acne. The study, involving 140 women with mild-to-moderate acne, met safety and tolerability endpoints with no adverse events reported. Statistically significant improvements were observed in skin appearance metrics, including inflammatory lesion counts (48.3% reduction, p0.0001) and non-inflammatory lesions (36.3% reduction, p<0.0001). However, no meaningful efficacy difference was noted compared to the vehicle. Subject satisfaction indicated preference for BX001 in reducing redness and improving skin feel.
BiomX (NYSE: PHGE) has entered a licensing agreement with Maruho Co. Ltd., granting Maruho the right of first offer for BX005, a product targeting atopic dermatitis, set to begin after Phase 1/2 trial results in 2022. Additionally, Maruho will invest $3 million in BiomX, supporting the ongoing study. BX005 aims to combat Staphylococcus aureus to improve skin microbiome health. BiomX’s innovative phage-based approach highlights its potential in addressing dermatological issues. The announcement marks a significant collaboration in one of the largest dermatology markets.
BiomX Inc. (NYSE American: PHGE), a clinical-stage microbiome company, announced that CEO Jonathan Solomon will present at three virtual investor events in September 2021. The events include the H.C. Wainwright 23rd Annual Global Investments Conference on September 13, the Oppenheimer Virtual Fall Healthcare Life Science & MedTech Summit on September 20, and the Cantor 2021 Virtual Global Healthcare Conference on September 30. Live webcasts will be available on BiomX's website, and archived materials will be accessible post-event.
BiomX (PHGE) announced a financial update for Q2 2021, highlighting a cash balance of $47.3 million, enabling operations until mid-2023. The company completed a $15 million equity raise and secured a $30 million debt agreement. Four clinical data readouts are expected by mid-2022, including Phase 2 results for acne treatment BX001 due in October. R&D expenses increased to $3.8 million, with a net loss of $7.3 million for the quarter. Upcoming milestones include trials for atopic dermatitis and cystic fibrosis therapies.
BiomX Inc. (PHGE) announced a conference call and webcast on August 16, 2021, at 8:00 a.m. EDT to discuss its second-quarter financial results and provide business updates. The company specializes in developing natural and engineered phage therapies targeting pathogenic bacteria affecting skin and chronic diseases, including inflammatory bowel disease and colorectal cancer. Investors can access the live and archived webcast via BiomX's website.
BiomX (NYSE American: PHGE) has announced a registered direct offering of 3,750,000 shares and warrants for a total expected gross of $15 million. The offering price is set at $4.00 per share, with warrants exercisable for 0.75 shares at $5.00 each, expiring in five years. The proceeds will support clinical trials and general corporate purposes. The closing date is anticipated around July 28, 2021, pending customary conditions. The offering follows an effective shelf registration statement declared by the SEC in December 2020.
BiomX Inc. (PHGE) announced promising preclinical results for its phage therapy candidate, BX005, targeting Staphylococcus aureus in atopic dermatitis. Presented at the Revolutionizing Atopic Dermatitis 2021 Virtual Conference, the results indicate BX005 efficiently eradicates harmful bacteria without mutant strain emergence. CEO Jonathan Solomon emphasized its potential for safer, effective treatment options, especially for children. BiomX expects to share Phase 2 safety and efficacy results in early 2022. The conference presentations occurred on June 13 and will continue on June 17-18, 2021.
BiomX (PHGE) announced promising preclinical results for BX004, a phage therapy targeting Pseudomonas aeruginosa in cystic fibrosis patients. Presented at the 44th European Cystic Fibrosis Conference, the data demonstrated BX004's effectiveness in reducing bacterial levels encased in biofilm, outperforming two antibiotics. Following these results, BiomX plans to advance BX004 to a Phase 1b/2a trial, with outcomes from Part 1 expected in Q1 2022. This advancement indicates the company's commitment to innovative therapies addressing chronic diseases.
BiomX (PHGE) reported Q1 2021 financial results, highlighting progress in clinical trials for its phage therapies. The company completed enrollment of 140 patients in a Phase 2 study of BX001 for acne, with results expected in Q3 and Q4. Positive safety data from BX002 for Inflammatory Bowel Disease prompted a transition to a Phase 1b/2a trial for BX003. Cash on hand was $53.6 million, supporting operations into mid-2022. R&D expenses increased to $5.8 million, and the net loss rose to $8.4 million, compared to $5.9 million in Q1 2020.